Xeris Biopharma Holdings, Inc. (FRA:2B30)

Germany · Delayed Price · Currency is EUR

5.63

-0.24 (-4.09%)

At close: Feb 20, 2026

Revenue by Segment

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017	FY 2016
Period Ending	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020	Dec '19 Dec 31, 2019	Dec '18 Dec 31, 2018	Dec '17 Dec 31, 2017	Dec '16 Dec 31, 2016
Pharmaceuticals	203.07M	163.91M	110.25M	49.59M	20.44M
Pharmaceuticals Growth	23.89%	48.68%	122.32%	142.67%	650.73%
Total	203.07M	163.91M	110.25M	49.59M	20.44M
Total Growth	23.89%	48.68%	122.32%	142.67%	650.73%

Revenue by Geography

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017	FY 2016
Period Ending	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020	Dec '19 Dec 31, 2019	Dec '18 Dec 31, 2018	Dec '17 Dec 31, 2017	Dec '16 Dec 31, 2016
United States	203.07M	163.91M	110.25M	49.59M	20.44M
United States Growth	23.89%	48.68%	122.32%	142.67%	650.73%
Total	203.07M	163.91M	110.25M	49.59M	20.44M
Total Growth	23.89%	48.68%	122.32%	142.67%	650.73%

Source: S&P Global Market Intelligence.